Delsie Braganza

Delsie joined the Focal Point Research team in 2011 and has been an invaluable asset for our clients. With her strong regulatory and quality assurance background, she is able to help clients understand the Canadian and US requirements, set targets to achieve compliance, and attain their goals to get products to market.

Delsie is able to audit facilities, set up and maintain GMP compliant facilities, develop strong quality management systems, and co-ordinate successful Health Canada inspections. In addition to this, Delsie oversees all regulatory compliance reviews and submissions made to Health Canada and the US FDA.

Delsie obtained an Honours Bachelor of Science (Hons. B. Sc.) in Pharmaceutical Chemistry from the University of Toronto, Post-Graduate Certificate in Pharmaceutical Regulatory Affairs and Quality Operations (RAQ) from Seneca College and Regulatory Affairs Certification (RAC) from the Regulatory Affairs Professional Society (RAPS).

When she’s not learning something new, Delsie loves spending time with family, going on road trips or long walks, and swimming.

Articles

If you would like to be added to our newsletter, please send an email to mail@focalpointresearch.net with the subject line ‘Receive FPR Newsletter’.

Why I Developed Lectures On Innovation

Jan 22, 2020

During the course of my career, I have seen fortunes made and fortunes lost. I have seen companies start in a basement and within five years sell for tens or hundreds of millions of dollars. I have also seen entrepreneurs having to sell their homes and cars and move...

Update on Nitrosamine Impurities in Pharmaceutical Products

Jan 7, 2020

Health Canada has updated its assessment requirements for Nitrosamines in pharmaceutical products. Nitrosamines are, defined by the World Health Organization, as “any molecule containing the nitroso functional group. These molecules are of concern because nitrosamine...

New Changes to Health Canada’s Cosmetic Ingredient Hotlist

Dec 23, 2019

Earlier this month, Health Canada released a list of new amendments to both the Restricted and Prohibited Cosmetic Ingredient Hotlists. The list included changes to the classification or conditions of use on four ingredients, all already present on the Cosmetic...

Health Canada Announces the Creation of a New Medical Devices Directorate

Dec 18, 2019

Health Canada has announced the creation of a new Medical Devices Directorate (MDD). This was done in order to account for and accurately reflect the current medical device industry, which has evolved drastically over the past several years. The new Directorate will...

European Commission Adopts Major Changes to Titanium Dioxide Classification

Nov 27, 2019

Early last month the European Commission (EC) adopted the 14th adaptation to technical progress (ATP) of the Classification and Labelling (CLP) Regulation. Within this adaptation are 28 proposed changes to the harmonised classification and labelling of substances. One...

Everything You Need To Know About Animal Testing Bans: Where They Stand And Where They Are Headed

Nov 12, 2019

Animal testing is, quite possibly, one of the most controversial and widely debated ethical issues in the cosmetic, personal care and healthcare industries. It is an issue that has gained an immense amount of traction in recent years, and rightly so, with numerous...

Feeling Blue: Can Blue Light Damage Your Skin?

Oct 22, 2019

While the general public is largely aware of the harmful effects ultraviolet (UV) light can have on our bodies, as well as the basic measures that should be taken to protect ourselves against such effects, the dangers surrounding blue light seem to go relatively left...

EPA’s Proposed Prioritization of Chemical Substances

Oct 2, 2019

Last month the United States Environmental Protection Agency (EPA) released a list of 20 chemical substances that they proposed be designated as High Priority Substances. The list, which was released as required under the Toxic Substances Control Act (TSCA), is...

503A Bulks List Prepares for Five Potential New Additions

Sep 25, 2019

The U.S. Food and Drug Administration (FDA) has officially released a proposed rule to amend the list of bulk drug substances that can be used to compound drug products with the addition of five new substances to the list. If approved, glutaraldehyde, glycolic acid,...

Update on Titanium Dioxide in Sunscreens

Sep 12, 2019

Currently, the Canadian Natural Health Products Ingredients Database (NHPID) lists Titanium dioxide (TiO2) as an opacifying agent and color additive for topical use, but is NOT permitted in sunscreens for these uses. However, according to Cosmetics Alliance Canada,...

« Older Entries

Next Entries »

“Focal Point Research has consistently and professionally looked after regulatory and quality issues of our brand for years. Through a courteous and knowledgeable team, they have managed to navigate us through an ever changing regulatory landscape while maintaining our interests, and allowed us to correctly distribute and sell within Canada.”

“I have truly enjoyed working with you over the last 8 years! You and your team have been an amazing resource for me. I have always been impressed by the knowledge and professionalism of everyone at Focal Point, which is a true testament to your leadership.”

Connect With Us

The Focal Point Research team is ready to help with all of your scientific and regulatory needs. Our team has the experience and expertise you need to see your product to market and we are eager to help you.

181 Lakeshore Road E. Mississauga, ON

1 (905) 271 2709

mail@focalpointresearch.net

Delsie Braganza

Jennifer Porter, BA Psychology, MBA – President & CEO

Articles

If you would like to be added to our newsletter, please send an email to mail@focalpointresearch.net with the subject line ‘Receive FPR Newsletter’.

Connect With Us